Substantia Nigra Pars Compacta (SNc) Dopaminergic Neurons

📖 Wiki Page

cell711 wordssynced 2026-04-02

Substantia Nigra Pars Compacta (SNc) Dopaminergic Neurons

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Substantia Nigra Pars Compacta (SNc) Dopaminergic Neurons</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Midbrain Dopaminergic Neurons</td>
</tr>
<tr>
<td class="label">Subcategory</td>
<td>Nigrostriatal Pathway</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Human, Mouse, Rat, Non-human Primates</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Ventral Midbrain</td>
</tr>
<tr>
<td class="label">Neurotransmitters</td>
<td>Dopamine, GABA</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000700](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000700)</td>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000700](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000700)</td>
</tr>
</table>

Introduction

Substantia Nigra Pars Compacta (Snc) Dopaminergic Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

...

Substantia Nigra Pars Compacta (SNc) Dopaminergic Neurons

Introduction

The substantia nigra pars compacta (SNc) is the most prominently affected brain region in Parkinson's disease. These dopaminergic neurons project to the striatum (the nigrostriatal pathway) and are essential for motor control, reward processing, and various cognitive functions.

Overview

Mermaid diagram (expand to render)

Multi-Taxonomy Classification

Taxonomy Database Cross-References

Morphology & Electrophysiology

Morphology: dopaminergic neuron (source: Cell Ontology)
Morphology can be inferred from Cell Ontology classification

PanglaoDB Marker Cross-References

Unknown (PanglaoDB):

External Database Links

[Cell Ontology (CL:0000700)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000700)
[OBO Foundry (CL:0000700)](http://purl.obolibrary.org/obo/CL_0000700)
[Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
[CellxGene Census](https://cellxgene.cziscience.com/)
[Human Cell Atlas](https://www.humancellatlas.org/)
[PanglaoDB](https://panglaodb.se/)

Taxonomy & Classification

PanglaoDB Marker Cross-References

Unknown (PanglaoDB):

External Database Links

[Cell Ontology (CL:0000700)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000700)
[OBO Foundry (CL:0000700)](http://purl.obolibrary.org/obo/CL_0000700)
[Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
[CellxGene Census](https://cellxgene.cziscience.com/)
[PanglaoDB](https://panglaodb.se/)

Morphology and Markers

SNc neurons have distinctive features:

Melanized neurons: Contains neuromelanin (in humans)
Large dendritic trees: Extensive local arborizations
Long axons: Project to dorsal striatum

Key molecular markers:

TH (Tyrosine hydroxylase): Rate-limiting enzyme in dopamine synthesis
DAT (SLC6A3): Dopamine transporter
VMAT2 (SLC18A2): Vesicular monoamine transporter
Pitx3: Transcription factor for SNc neuron development
NR4A2 (Nurr1): Dopaminergic neuron identity factor

Normal Function

Motor Control

Nigrostriatal pathway initiates and regulates movement
Dopamine release in striatum enables smooth, coordinated movements
Enables motor learning and habit formation

Reward Processing

Part of mesolimbic and mesocortical pathways
Encodes reward prediction errors
Motivation and reinforcement learning

Cognitive Functions

Working memory enhancement
Attention and executive function
Time perception

Neurophysiology

Autonomous pacemaking activity (~4-10 Hz)
Burst firing in response to rewards
Calcium-dependent pacemaking (L-type channels)

Disease Vulnerability

Parkinson's Disease (PD)

Selective vulnerability: SNc neurons degenerate in PD
Mechanisms: Mitochondrial dysfunction, oxidative stress, neuroinflammation
Protein inclusions: Lewy bodies (α-synuclein)
Symptoms: Tremor, bradykinesia, rigidity, postural instability
8 PubMed references on SNc in PD[@fearnley1991][@damier1999][@kalia2015][@poewe2017][@surmeier2017][@schapira2017][@hirsch2019][@braak2003]

Alzheimer's Disease (AD)

SNc involvement in later stages of AD
Contributes to motor symptoms in AD with parkinsonism
Lewy body pathology in SNc in DLB/PD with dementia
8 PubMed references on SNc in AD[@jellinger2019][@kalaitzakis2008][@dugger2014][@attems2018][@ryman2020][@bassetti2021][@weil2022][@halliday2023]

Progressive Supranuclear Palsy (PSP)

SNc degeneration contributes to parkinsonism
Tau pathology in SNc neurons
8 PubMed references on SNc in PSP[@steele1964][@williams2010][@litvan2019][@respondek2014][@ahmed2019][@kovacs2020][@ghiglieri2021][@masliah2022]

Multiple System Atrophy (MSA)

SNc degeneration in parkinsonian variant
Combined with autonomic dysfunction
8 PubMed references on SNc in MSA[@wenning2022][@jellinger2019a][@gilman2008][@ozawa2021][@fanciulli2020][@singer2021][@kaufmann2022][@schmeichel2023]

Transcriptomic Profile

SNc neurons show molecular heterogeneity:

Calbindin+ cluster: Ventral tier, more vulnerable
Calbindin- cluster: Dorsal tier, relatively spared
Aldh1a1+ cluster: Specific vulnerability factors
Vglut2+ cluster: Glutamatergic phenotype neurons

Key genes: TH, DAT, VMAT2, PANK2, LRRK2, GBA1, SNCA

Therapeutic Implications

Pharmacological Treatments

Levodopa: Dopamine precursor
Dopamine agonists: Pramipexole, ropinirole
MAO-B inhibitors: Selegiline, rasagiline

Surgical Interventions

Deep brain stimulation: STN or GPi targets
Cell replacement: Investigational dopamine cell transplantation

Emerging Therapies

Gene therapy: AAV-based dopamine enzyme delivery
Neuroprotective agents: Targeting LRRK2,GBA1
Alpha-synuclein targeting: Immunotherapies, small molecules

Background

The study of Substantia Nigra Pars Compacta (Snc) Dopaminergic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[Substantia Nigra - Neuroanatomy at University of Queensland](https://neuroscience.ug.edu.au)
[Dopamine and Parkinson's - Nature Reviews](https://www.nature.com/nrn)
[Parkinson's Disease - Michael J. Fox Foundation](https://www.michaeljfox.org)
[PD Pathology - Stanford Neuroscience](https://neuroscience.stanford.edu)

📖 View canonical wiki page →